Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary Revance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017
- Conference Call Scheduled for Thursday, November 2, 2017 at 4:30pm ET - NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will
View HTML
Toggle Summary Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis
- Company expects to report topline eight-week results at the end of the year - NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced it has
View HTML
Toggle Summary Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the Cantor Fitzgerald 2017 Global Healthcare Conference in
View HTML
Toggle Summary Revance Appoints Mark Foley to its Board of Directors
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced that Mark Foley has been appointed to Revance's Board of Directors, effective September
View HTML
Toggle Summary Revance to Participate in the 2017 Wells Fargo Securities Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the 2017 Wells Fargo Securities Healthcare Conference in
View HTML
Toggle Summary Revance Releases Second Quarter 2017 Results
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced results for the second quarter ended June 30, 2017 .
View HTML
Toggle Summary Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics
Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics NEWARK, Calif., August 2, 2017 – Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating
View HTML
Toggle Summary Revance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017
Conference Call Scheduled for Thursday, August 3, 2017 at 4:30pm ET NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will
View HTML
Toggle Summary Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery
- RT002 injectable 40-unit dose under study for the treatment of glabellar lines demonstrated statistical and clinical superiority over BOTOX* Cosmetic for a range of efficacy outcomes and achieved six-month duration of effect - NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc.
View HTML
Toggle Summary Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial
- Poster on display today to be presented during late-breaking session on June 7, 2017 , at 21 st International Congress of Parkinson's Disease and Movement Disorders - NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools
Printed Materials
Download Library
RSS News Feeds
Search